ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Epidermolysis Bullosa Therapeutics Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-14V13988
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Epidermolysis Bullosa Therapeutics Market Insights Forecast to 2029
BUY CHAPTERS

Global Epidermolysis Bullosa Therapeutics Market Research Report 2025

Code: QYRE-Auto-14V13988
Report
January 2025
Pages:95
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Birken AG
Fibrocell Science, Inc.
GlaxoSmithKline PLC
InMed Pharmaceuticals Inc.
Karus Therapeutics Limited
ProQR Therapeutics N.V.
RegeneRx Biopharmaceuticals, Inc.
Scioderm
Stratatech Corporation
TWi Pharmaceuticals, Inc.
WAVE Life Sciences Ltd

Epidermolysis Bullosa Therapeutics Market Size

The global market for Epidermolysis Bullosa Therapeutics was valued at US$ 1714 million in the year 2024 and is projected to reach a revised size of US$ 2366 million by 2031, growing at a CAGR of 4.8% during the forecast period.

Epidermolysis Bullosa Therapeutics Market

Epidermolysis Bullosa Therapeutics Market

North American market for Epidermolysis Bullosa Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Epidermolysis Bullosa Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Epidermolysis Bullosa Therapeutics include Birken AG, Fibrocell Science, Inc., GlaxoSmithKline Plc, InMed Pharmaceuticals Inc., Karus Therapeutics Limited, ProQR Therapeutics N.V., RegeneRx Biopharmaceuticals, Inc., Scioderm, Inc., Stratatech Corporation, TWi Pharmaceuticals, Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Epidermolysis Bullosa Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Epidermolysis Bullosa Therapeutics.
The Epidermolysis Bullosa Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Epidermolysis Bullosa Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Epidermolysis Bullosa Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Epidermolysis Bullosa Therapeutics Market Report

Report Metric Details
Report Name Epidermolysis Bullosa Therapeutics Market
Accounted market size in year US$ 1714 million
Forecasted market size in 2031 US$ 2366 million
CAGR 4.8%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • EB-201
  • FCX-007
  • ICX-RHY
  • INM-750
  • Others
Segment by Application
  • Clinic
  • Hospital
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Birken AG, Fibrocell Science, Inc., GlaxoSmithKline Plc, InMed Pharmaceuticals Inc., Karus Therapeutics Limited, ProQR Therapeutics N.V., RegeneRx Biopharmaceuticals, Inc., Scioderm, Inc., Stratatech Corporation, TWi Pharmaceuticals, Inc., WAVE Life Sciences Ltd.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Epidermolysis Bullosa Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Epidermolysis Bullosa Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Epidermolysis Bullosa Therapeutics Market growing?

Ans: The Epidermolysis Bullosa Therapeutics Market witnessing a CAGR of 4.8% during the forecast period 2025-2031.

What is the Epidermolysis Bullosa Therapeutics Market size in 2031?

Ans: The Epidermolysis Bullosa Therapeutics Market size in 2031 will be US$ 2366 million.

Who are the main players in the Epidermolysis Bullosa Therapeutics Market report?

Ans: The main players in the Epidermolysis Bullosa Therapeutics Market are Birken AG, Fibrocell Science, Inc., GlaxoSmithKline Plc, InMed Pharmaceuticals Inc., Karus Therapeutics Limited, ProQR Therapeutics N.V., RegeneRx Biopharmaceuticals, Inc., Scioderm, Inc., Stratatech Corporation, TWi Pharmaceuticals, Inc., WAVE Life Sciences Ltd.

What are the Application segmentation covered in the Epidermolysis Bullosa Therapeutics Market report?

Ans: The Applications covered in the Epidermolysis Bullosa Therapeutics Market report are Clinic, Hospital, Others

What are the Type segmentation covered in the Epidermolysis Bullosa Therapeutics Market report?

Ans: The Types covered in the Epidermolysis Bullosa Therapeutics Market report are EB-201, FCX-007, ICX-RHY, INM-750, Others

Recommended Reports

Skin Disease Therapies

Scar & Wound Solutions

Rare Disease Treatments

1 Epidermolysis Bullosa Therapeutics Market Overview
1.1 Product Definition
1.2 Epidermolysis Bullosa Therapeutics by Type
1.2.1 Global Epidermolysis Bullosa Therapeutics Market Value Comparison by Type (2024 VS 2031)
1.2.2 EB-201
1.2.3 FCX-007
1.2.4 ICX-RHY
1.2.5 INM-750
1.2.6 Others
1.3 Epidermolysis Bullosa Therapeutics by Application
1.3.1 Global Epidermolysis Bullosa Therapeutics Market Value by Application (2024 VS 2031)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Epidermolysis Bullosa Therapeutics Market Size Estimates and Forecasts
1.4.1 Global Epidermolysis Bullosa Therapeutics Revenue 2020-2031
1.4.2 Global Epidermolysis Bullosa Therapeutics Sales 2020-2031
1.4.3 Global Epidermolysis Bullosa Therapeutics Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Epidermolysis Bullosa Therapeutics Market Competition by Manufacturers
2.1 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Manufacturers (2020-2025)
2.2 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Epidermolysis Bullosa Therapeutics Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Epidermolysis Bullosa Therapeutics, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Epidermolysis Bullosa Therapeutics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Epidermolysis Bullosa Therapeutics, Product Type & Application
2.7 Global Key Manufacturers of Epidermolysis Bullosa Therapeutics, Date of Enter into This Industry
2.8 Global Epidermolysis Bullosa Therapeutics Market Competitive Situation and Trends
2.8.1 Global Epidermolysis Bullosa Therapeutics Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Epidermolysis Bullosa Therapeutics Players Market Share by Revenue
2.8.3 Global Epidermolysis Bullosa Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Epidermolysis Bullosa Therapeutics Market Scenario by Region
3.1 Global Epidermolysis Bullosa Therapeutics Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Epidermolysis Bullosa Therapeutics Sales by Region: 2020-2031
3.2.1 Global Epidermolysis Bullosa Therapeutics Sales by Region: 2020-2025
3.2.2 Global Epidermolysis Bullosa Therapeutics Sales by Region: 2026-2031
3.3 Global Epidermolysis Bullosa Therapeutics Revenue by Region: 2020-2031
3.3.1 Global Epidermolysis Bullosa Therapeutics Revenue by Region: 2020-2025
3.3.2 Global Epidermolysis Bullosa Therapeutics Revenue by Region: 2026-2031
3.4 North America Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country
3.4.1 North America Epidermolysis Bullosa Therapeutics Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Epidermolysis Bullosa Therapeutics Sales by Country (2020-2031)
3.4.3 North America Epidermolysis Bullosa Therapeutics Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country
3.5.1 Europe Epidermolysis Bullosa Therapeutics Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Epidermolysis Bullosa Therapeutics Sales by Country (2020-2031)
3.5.3 Europe Epidermolysis Bullosa Therapeutics Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Epidermolysis Bullosa Therapeutics Market Facts & Figures by Region
3.6.1 Asia Pacific Epidermolysis Bullosa Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Epidermolysis Bullosa Therapeutics Sales by Region (2020-2031)
3.6.3 Asia Pacific Epidermolysis Bullosa Therapeutics Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country
3.7.1 Latin America Epidermolysis Bullosa Therapeutics Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Epidermolysis Bullosa Therapeutics Sales by Country (2020-2031)
3.7.3 Latin America Epidermolysis Bullosa Therapeutics Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country
3.8.1 Middle East and Africa Epidermolysis Bullosa Therapeutics Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Epidermolysis Bullosa Therapeutics Sales by Country (2020-2031)
3.8.3 Middle East and Africa Epidermolysis Bullosa Therapeutics Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Epidermolysis Bullosa Therapeutics Sales by Type (2020-2031)
4.1.1 Global Epidermolysis Bullosa Therapeutics Sales by Type (2020-2025)
4.1.2 Global Epidermolysis Bullosa Therapeutics Sales by Type (2026-2031)
4.1.3 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2020-2031)
4.2 Global Epidermolysis Bullosa Therapeutics Revenue by Type (2020-2031)
4.2.1 Global Epidermolysis Bullosa Therapeutics Revenue by Type (2020-2025)
4.2.2 Global Epidermolysis Bullosa Therapeutics Revenue by Type (2026-2031)
4.2.3 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2020-2031)
4.3 Global Epidermolysis Bullosa Therapeutics Price by Type (2020-2031)
5 Segment by Application
5.1 Global Epidermolysis Bullosa Therapeutics Sales by Application (2020-2031)
5.1.1 Global Epidermolysis Bullosa Therapeutics Sales by Application (2020-2025)
5.1.2 Global Epidermolysis Bullosa Therapeutics Sales by Application (2026-2031)
5.1.3 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2020-2031)
5.2 Global Epidermolysis Bullosa Therapeutics Revenue by Application (2020-2031)
5.2.1 Global Epidermolysis Bullosa Therapeutics Revenue by Application (2020-2025)
5.2.2 Global Epidermolysis Bullosa Therapeutics Revenue by Application (2026-2031)
5.2.3 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Application (2020-2031)
5.3 Global Epidermolysis Bullosa Therapeutics Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Birken AG
6.1.1 Birken AG Company Information
6.1.2 Birken AG Description and Business Overview
6.1.3 Birken AG Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Birken AG Epidermolysis Bullosa Therapeutics Product Portfolio
6.1.5 Birken AG Recent Developments/Updates
6.2 Fibrocell Science, Inc.
6.2.1 Fibrocell Science, Inc. Company Information
6.2.2 Fibrocell Science, Inc. Description and Business Overview
6.2.3 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
6.2.5 Fibrocell Science, Inc. Recent Developments/Updates
6.3 GlaxoSmithKline Plc
6.3.1 GlaxoSmithKline Plc Company Information
6.3.2 GlaxoSmithKline Plc Description and Business Overview
6.3.3 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.3.4 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Product Portfolio
6.3.5 GlaxoSmithKline Plc Recent Developments/Updates
6.4 InMed Pharmaceuticals Inc.
6.4.1 InMed Pharmaceuticals Inc. Company Information
6.4.2 InMed Pharmaceuticals Inc. Description and Business Overview
6.4.3 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.4.4 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
6.4.5 InMed Pharmaceuticals Inc. Recent Developments/Updates
6.5 Karus Therapeutics Limited
6.5.1 Karus Therapeutics Limited Company Information
6.5.2 Karus Therapeutics Limited Description and Business Overview
6.5.3 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Product Portfolio
6.5.5 Karus Therapeutics Limited Recent Developments/Updates
6.6 ProQR Therapeutics N.V.
6.6.1 ProQR Therapeutics N.V. Company Information
6.6.2 ProQR Therapeutics N.V. Description and Business Overview
6.6.3 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.6.4 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Product Portfolio
6.6.5 ProQR Therapeutics N.V. Recent Developments/Updates
6.7 RegeneRx Biopharmaceuticals, Inc.
6.7.1 RegeneRx Biopharmaceuticals, Inc. Company Information
6.7.2 RegeneRx Biopharmaceuticals, Inc. Description and Business Overview
6.7.3 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.7.4 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
6.7.5 RegeneRx Biopharmaceuticals, Inc. Recent Developments/Updates
6.8 Scioderm, Inc.
6.8.1 Scioderm, Inc. Company Information
6.8.2 Scioderm, Inc. Description and Business Overview
6.8.3 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
6.8.5 Scioderm, Inc. Recent Developments/Updates
6.9 Stratatech Corporation
6.9.1 Stratatech Corporation Company Information
6.9.2 Stratatech Corporation Description and Business Overview
6.9.3 Stratatech Corporation Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Stratatech Corporation Epidermolysis Bullosa Therapeutics Product Portfolio
6.9.5 Stratatech Corporation Recent Developments/Updates
6.10 TWi Pharmaceuticals, Inc.
6.10.1 TWi Pharmaceuticals, Inc. Company Information
6.10.2 TWi Pharmaceuticals, Inc. Description and Business Overview
6.10.3 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.10.4 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
6.10.5 TWi Pharmaceuticals, Inc. Recent Developments/Updates
6.11 WAVE Life Sciences Ltd.
6.11.1 WAVE Life Sciences Ltd. Company Information
6.11.2 WAVE Life Sciences Ltd. Description and Business Overview
6.11.3 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.11.4 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Product Portfolio
6.11.5 WAVE Life Sciences Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Epidermolysis Bullosa Therapeutics Industry Chain Analysis
7.2 Epidermolysis Bullosa Therapeutics Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Epidermolysis Bullosa Therapeutics Production Mode & Process Analysis
7.4 Epidermolysis Bullosa Therapeutics Sales and Marketing
7.4.1 Epidermolysis Bullosa Therapeutics Sales Channels
7.4.2 Epidermolysis Bullosa Therapeutics Distributors
7.5 Epidermolysis Bullosa Therapeutics Customer Analysis
8 Epidermolysis Bullosa Therapeutics Market Dynamics
8.1 Epidermolysis Bullosa Therapeutics Industry Trends
8.2 Epidermolysis Bullosa Therapeutics Market Drivers
8.3 Epidermolysis Bullosa Therapeutics Market Challenges
8.4 Epidermolysis Bullosa Therapeutics Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Birken AG
Fibrocell Science, Inc.
GlaxoSmithKline PLC
InMed Pharmaceuticals Inc.
Karus Therapeutics Limited
ProQR Therapeutics N.V.
RegeneRx Biopharmaceuticals, Inc.
Scioderm
Stratatech Corporation
TWi Pharmaceuticals, Inc.
WAVE Life Sciences Ltd
List of Tables
 Table 1. Global Epidermolysis Bullosa Therapeutics Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Epidermolysis Bullosa Therapeutics Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Epidermolysis Bullosa Therapeutics Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) of Key Manufacturers (2020-2025)
 Table 5. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Epidermolysis Bullosa Therapeutics Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Epidermolysis Bullosa Therapeutics Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Epidermolysis Bullosa Therapeutics, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Epidermolysis Bullosa Therapeutics, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Epidermolysis Bullosa Therapeutics, Product Type & Application
 Table 12. Global Key Manufacturers of Epidermolysis Bullosa Therapeutics, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Epidermolysis Bullosa Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Epidermolysis Bullosa Therapeutics as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Epidermolysis Bullosa Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Epidermolysis Bullosa Therapeutics Sales by Region (2020-2025) & (K Pcs)
 Table 18. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Region (2020-2025)
 Table 19. Global Epidermolysis Bullosa Therapeutics Sales by Region (2026-2031) & (K Pcs)
 Table 20. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Region (2026-2031)
 Table 21. Global Epidermolysis Bullosa Therapeutics Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Region (2020-2025)
 Table 23. Global Epidermolysis Bullosa Therapeutics Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Region (2026-2031)
 Table 25. North America Epidermolysis Bullosa Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025) & (K Pcs)
 Table 27. North America Epidermolysis Bullosa Therapeutics Sales by Country (2026-2031) & (K Pcs)
 Table 28. North America Epidermolysis Bullosa Therapeutics Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Epidermolysis Bullosa Therapeutics Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Epidermolysis Bullosa Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025) & (K Pcs)
 Table 32. Europe Epidermolysis Bullosa Therapeutics Sales by Country (2026-2031) & (K Pcs)
 Table 33. Europe Epidermolysis Bullosa Therapeutics Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Epidermolysis Bullosa Therapeutics Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Epidermolysis Bullosa Therapeutics Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Epidermolysis Bullosa Therapeutics Sales by Region (2020-2025) & (K Pcs)
 Table 37. Asia Pacific Epidermolysis Bullosa Therapeutics Sales by Region (2026-2031) & (K Pcs)
 Table 38. Asia Pacific Epidermolysis Bullosa Therapeutics Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Epidermolysis Bullosa Therapeutics Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Epidermolysis Bullosa Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025) & (K Pcs)
 Table 42. Latin America Epidermolysis Bullosa Therapeutics Sales by Country (2026-2031) & (K Pcs)
 Table 43. Latin America Epidermolysis Bullosa Therapeutics Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Epidermolysis Bullosa Therapeutics Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Epidermolysis Bullosa Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025) & (K Pcs)
 Table 47. Middle East and Africa Epidermolysis Bullosa Therapeutics Sales by Country (2026-2031) & (K Pcs)
 Table 48. Middle East and Africa Epidermolysis Bullosa Therapeutics Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Epidermolysis Bullosa Therapeutics Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Type (2020-2025)
 Table 51. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Type (2026-2031)
 Table 52. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2020-2025)
 Table 53. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2026-2031)
 Table 54. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2020-2025)
 Table 57. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2026-2031)
 Table 58. Global Epidermolysis Bullosa Therapeutics Price (USD/Pcs) by Type (2020-2025)
 Table 59. Global Epidermolysis Bullosa Therapeutics Price (USD/Pcs) by Type (2026-2031)
 Table 60. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Application (2020-2025)
 Table 61. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Application (2026-2031)
 Table 62. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2020-2025)
 Table 63. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2026-2031)
 Table 64. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Application (2020-2025)
 Table 67. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Application (2026-2031)
 Table 68. Global Epidermolysis Bullosa Therapeutics Price (USD/Pcs) by Application (2020-2025)
 Table 69. Global Epidermolysis Bullosa Therapeutics Price (USD/Pcs) by Application (2026-2031)
 Table 70. Birken AG Company Information
 Table 71. Birken AG Description and Business Overview
 Table 72. Birken AG Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 73. Birken AG Epidermolysis Bullosa Therapeutics Product
 Table 74. Birken AG Recent Developments/Updates
 Table 75. Fibrocell Science, Inc. Company Information
 Table 76. Fibrocell Science, Inc. Description and Business Overview
 Table 77. Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 78. Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Product
 Table 79. Fibrocell Science, Inc. Recent Developments/Updates
 Table 80. GlaxoSmithKline Plc Company Information
 Table 81. GlaxoSmithKline Plc Description and Business Overview
 Table 82. GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 83. GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Product
 Table 84. GlaxoSmithKline Plc Recent Developments/Updates
 Table 85. InMed Pharmaceuticals Inc. Company Information
 Table 86. InMed Pharmaceuticals Inc. Description and Business Overview
 Table 87. InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 88. InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Product
 Table 89. InMed Pharmaceuticals Inc. Recent Developments/Updates
 Table 90. Karus Therapeutics Limited Company Information
 Table 91. Karus Therapeutics Limited Description and Business Overview
 Table 92. Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 93. Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Product
 Table 94. Karus Therapeutics Limited Recent Developments/Updates
 Table 95. ProQR Therapeutics N.V. Company Information
 Table 96. ProQR Therapeutics N.V. Description and Business Overview
 Table 97. ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 98. ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Product
 Table 99. ProQR Therapeutics N.V. Recent Developments/Updates
 Table 100. RegeneRx Biopharmaceuticals, Inc. Company Information
 Table 101. RegeneRx Biopharmaceuticals, Inc. Description and Business Overview
 Table 102. RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 103. RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product
 Table 104. RegeneRx Biopharmaceuticals, Inc. Recent Developments/Updates
 Table 105. Scioderm, Inc. Company Information
 Table 106. Scioderm, Inc. Description and Business Overview
 Table 107. Scioderm, Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 108. Scioderm, Inc. Epidermolysis Bullosa Therapeutics Product
 Table 109. Scioderm, Inc. Recent Developments/Updates
 Table 110. Stratatech Corporation Company Information
 Table 111. Stratatech Corporation Description and Business Overview
 Table 112. Stratatech Corporation Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 113. Stratatech Corporation Epidermolysis Bullosa Therapeutics Product
 Table 114. Stratatech Corporation Recent Developments/Updates
 Table 115. TWi Pharmaceuticals, Inc. Company Information
 Table 116. TWi Pharmaceuticals, Inc. Description and Business Overview
 Table 117. TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 118. TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product
 Table 119. TWi Pharmaceuticals, Inc. Recent Developments/Updates
 Table 120. WAVE Life Sciences Ltd. Company Information
 Table 121. WAVE Life Sciences Ltd. Description and Business Overview
 Table 122. WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 123. WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Product
 Table 124. WAVE Life Sciences Ltd. Recent Developments/Updates
 Table 125. Key Raw Materials Lists
 Table 126. Raw Materials Key Suppliers Lists
 Table 127. Epidermolysis Bullosa Therapeutics Distributors List
 Table 128. Epidermolysis Bullosa Therapeutics Customers List
 Table 129. Epidermolysis Bullosa Therapeutics Market Trends
 Table 130. Epidermolysis Bullosa Therapeutics Market Drivers
 Table 131. Epidermolysis Bullosa Therapeutics Market Challenges
 Table 132. Epidermolysis Bullosa Therapeutics Market Restraints
 Table 133. Research Programs/Design for This Report
 Table 134. Key Data Information from Secondary Sources
 Table 135. Key Data Information from Primary Sources
 Table 136. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Epidermolysis Bullosa Therapeutics
 Figure 2. Global Epidermolysis Bullosa Therapeutics Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Epidermolysis Bullosa Therapeutics Market Share by Type: 2024 & 2031
 Figure 4. EB-201 Product Picture
 Figure 5. FCX-007 Product Picture
 Figure 6. ICX-RHY Product Picture
 Figure 7. INM-750 Product Picture
 Figure 8. Others Product Picture
 Figure 9. Global Epidermolysis Bullosa Therapeutics Market Value by Application (2020-2031) & (US$ Million)
 Figure 10. Global Epidermolysis Bullosa Therapeutics Market Share by Application: 2024 & 2031
 Figure 11. Clinic
 Figure 12. Hospital
 Figure 13. Others
 Figure 14. Global Epidermolysis Bullosa Therapeutics Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Epidermolysis Bullosa Therapeutics Market Size (2020-2031) & (US$ Million)
 Figure 16. Global Epidermolysis Bullosa Therapeutics Sales (2020-2031) & (K Pcs)
 Figure 17. Global Epidermolysis Bullosa Therapeutics Average Price (USD/Pcs) & (2020-2031)
 Figure 18. Epidermolysis Bullosa Therapeutics Report Years Considered
 Figure 19. Epidermolysis Bullosa Therapeutics Sales Share by Manufacturers in 2024
 Figure 20. Global Epidermolysis Bullosa Therapeutics Revenue Share by Manufacturers in 2024
 Figure 21. Global 5 and 10 Largest Epidermolysis Bullosa Therapeutics Players: Market Share by Revenue in Epidermolysis Bullosa Therapeutics in 2024
 Figure 22. Epidermolysis Bullosa Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 23. Global Epidermolysis Bullosa Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 24. North America Epidermolysis Bullosa Therapeutics Sales Market Share by Country (2020-2031)
 Figure 25. North America Epidermolysis Bullosa Therapeutics Revenue Market Share by Country (2020-2031)
 Figure 26. U.S. Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Canada Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Europe Epidermolysis Bullosa Therapeutics Sales Market Share by Country (2020-2031)
 Figure 29. Europe Epidermolysis Bullosa Therapeutics Revenue Market Share by Country (2020-2031)
 Figure 30. Germany Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. France Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. U.K. Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Italy Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Russia Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Asia Pacific Epidermolysis Bullosa Therapeutics Sales Market Share by Region (2020-2031)
 Figure 36. Asia Pacific Epidermolysis Bullosa Therapeutics Revenue Market Share by Region (2020-2031)
 Figure 37. China Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Japan Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. South Korea Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. India Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Australia Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Taiwan Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Indonesia Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Thailand Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Malaysia Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Philippines Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Latin America Epidermolysis Bullosa Therapeutics Sales Market Share by Country (2020-2031)
 Figure 48. Latin America Epidermolysis Bullosa Therapeutics Revenue Market Share by Country (2020-2031)
 Figure 49. Mexico Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Brazil Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Argentina Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Middle East and Africa Epidermolysis Bullosa Therapeutics Sales Market Share by Country (2020-2031)
 Figure 53. Middle East and Africa Epidermolysis Bullosa Therapeutics Revenue Market Share by Country (2020-2031)
 Figure 54. Turkey Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Saudi Arabia Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. U.A.E Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Global Sales Market Share of Epidermolysis Bullosa Therapeutics by Type (2020-2031)
 Figure 58. Global Revenue Market Share of Epidermolysis Bullosa Therapeutics by Type (2020-2031)
 Figure 59. Global Epidermolysis Bullosa Therapeutics Price (USD/Pcs) by Type (2020-2031)
 Figure 60. Global Sales Market Share of Epidermolysis Bullosa Therapeutics by Application (2020-2031)
 Figure 61. Global Revenue Market Share of Epidermolysis Bullosa Therapeutics by Application (2020-2031)
 Figure 62. Global Epidermolysis Bullosa Therapeutics Price (USD/Pcs) by Application (2020-2031)
 Figure 63. Epidermolysis Bullosa Therapeutics Value Chain
 Figure 64. Channels of Distribution (Direct Vs Distribution)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Dystrophic Epidermolysis Bullosa Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Dystrophic Epidermolysis Bullosa Management Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Autoimmune Disease Therapeutics Market Research Report 2024
Global Epidermal Cell Separator Market Research Report 2024
Bullous Pemphigoid Therapies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Bullous Keratopathy Market Research Report 2025
Global Recombinant Human Epidermal Growth Factor Market Research Report 2025
Global Globoid Cell Leukodystrophy Treatment Market Research Report 2024
Global Tissue Engineered Skin Substitutes Market Research Report 2025
Global Topical Keratolytics Market Research Report 2025
Global Proteinase K Market Research Report 2024
Global Advanced Scar Gel Market Research Report 2025
Global Tissue Freeze Spray Market Research Report 2025
Global Scleroderma Treatment Market Research Report 2025
Global Sandhoff Disease Therapeutics Market Research Report 2025
Birch Allergy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Acne Scar Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Epithelial Stem Cells Market Research Report 2025
Global Bis Stearamide EBS Market Research Report 2025
Global Wilsons Disease Treatment Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions